Guided Therapeutics (GTHP) EBIT Growth (1y) (2011 - 2025)
Guided Therapeutics (GTHP) EBIT Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.01 Bn | 175.72 Bn | 6.27 Bn | -20.56% |
| 2 | Stryker | 128.76 Bn | 125.88 Bn | 3.81 Bn | 11.83% |
| 3 | Medtronic | 108.90 Bn | 99.68 Bn | 6.41 Bn | 30.43% |
| 4 | Boston Scientific | 68.43 Bn | 66.98 Bn | 3.61 Bn | 19.54% |
| 5 | Edwards Lifesciences | 47.96 Bn | 44.29 Bn | 1.29 Bn | 20.97% |
| 6 | GE HealthCare Technologies | 28.29 Bn | 26.01 Bn | 1.98 Bn | -18.12% |
| 7 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 90.95% |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 25.44 Bn | 22.31 Bn | 2.07 Bn | 74.18% |
| 10 | Guided Therapeutics | 20.39 Mn | 20.32 Mn | 458,000.00 | -32.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -32.96% |
| Sep 30, 2025 | 13.55% |
| Jun 30, 2025 | -16.49% |
| Mar 31, 2025 | -15.32% |
| Dec 31, 2024 | -10.10% |
| Sep 30, 2024 | 9.95% |
| Jun 30, 2024 | 56.48% |
| Mar 31, 2024 | 57.41% |
| Dec 31, 2023 | 48.84% |
| Sep 30, 2023 | 49.10% |
| Jun 30, 2023 | -109.90% |
| Mar 31, 2023 | -90.29% |
| Dec 31, 2022 | -117.93% |
| Sep 30, 2022 | -151.33% |
| Jun 30, 2022 | -27.81% |
| Mar 31, 2022 | 46.17% |
| Dec 31, 2021 | -51.04% |
| Sep 30, 2021 | -218.30% |
| Jun 30, 2021 | -52.03% |
| Mar 31, 2021 | -240.08% |